Please login to the form below

Not currently logged in
Email:
Password:

hereditary angioedema

This page shows the latest hereditary angioedema news and features for those working in and with pharma, biotech and healthcare.

EMA starts rapid review of Shire’s HAE antibody

EMA starts rapid review of Shire’s HAE antibody

Shire could be months away from its first regulatory approval for hereditary angioedema (HAE) candidate lanadelumab as the EMA starts an accelerated review of the drug. ... The antibody - which targets and inhibits plasma kallikrein - is intended as a

Latest news

  • Shire completes $32bn Baxalta merger Shire completes $32bn Baxalta merger

    The pipeline will focus on therapy areas including haematology, immunology, neuroscience, lysosmal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE), and brings Baxalta's haemophilia franchise into the fold.

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    disease therapies across haematology, immunology, neuroscience, lysosomal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE).

  • Shire deal with Baxalta predicted this week Shire deal with Baxalta predicted this week

    Shire has been on the acquisition trail since a $55bn takeover by AbbVie was abandoned in 2014, agreeing a $65bn deal to buy Dyax in November 2015 - adding experimental hereditary angioedema

  • FDA grants fast track designation to Shire’s Cinryze FDA grants fast track designation to Shire’s Cinryze

    Cinryze is currently only approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE) and is used to prevent swelling or painful episodes.

  • Shire launches rare disease website Shire launches rare disease website

    Shire launches rare disease website. Hereditary angioedema sitesupports its Me, Not HAE campaign. ... Shire has launched an awareness website for hereditary angioedema (HAE) as part of its Me, Not HAE campaign.

More from news
Approximately 1 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Deal Watch August 2016 Deal Watch August 2016

    151. Valeant (US). Pharming (NL). Asset acquisition North America. Ruconest (recombinant human C1 esterase inhibitor) for treatment of acute Hereditary Angioedema with sales of $25m.

  • Deal Watch February 2016 Deal Watch February 2016

    Annapurna brings a portfolio of four AAV-based gene therapy programmes at the preclinical stage for alpha-1 antitrypsin deficiency, hereditary angioedema, cardiomyopathy associated with Friedreich's ataxia and severe allergy.

  • Deal Watch November 2015 Deal Watch November 2015

    hereditary angioedema (HAE). ... US. Abbreviations: HAE, Hereditary angioedema. 14th December 2015.

  • Deal Watch table for November 2013 Deal Watch table for November 2013

    Viropharm / Shire. Acquisition. Orphan drugs including Cinryze for prophylactic. treatment of hereditary angioedema.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics